Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Oxurion    OXUR   BE0003846632

OXURION

(OXUR)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
04/15/2019 04/16/2019 04/17/2019 04/18/2019 04/23/2019 Date
3.87(c) 3.86(c) 3.985(c) 3.855(c) 3.85 Last
45 762 24 784 39 624 102 161 14 382 Volume
-2.03% -0.26% +3.24% -3.26% -0.13% Change
More quotes
Financials (EUR)
Sales 2019 6,00 M
EBIT 2019 -34,0 M
Net income 2019 -30,0 M
Debt 2019 -
Yield 2019 -
Sales 2020 6,50 M
EBIT 2020 -33,5 M
Net income 2020 -32,0 M
Debt 2020 9,00 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 24,6x
EV / Sales2020 24,1x
Capitalization 148 M
More Financials
Company
Oxurion (formerly ThromboGenics) specializes in the research and development of bio-therapeutic products for treating cardiovascular diseases, ophthalmic disorders, and cancers. Net sales break down by source of income as follows: - sales of products (86.1%); - royalties (13.9%). 
Sector
Biotechnology & Medical Research
Calendar
05/07 | 08:00amShareholder meeting
More about the company
Surperformance© ratings of Oxurion
Trading Rating : - Investor Rating :
More Ratings
Latest news on OXURION
04/05OXURION : announces full enrollment of its Phase 2 trial evaluating efficacy and..
AQ
04/04OXURION : announces full enrollment of its Phase 2 trial evaluating efficacy and..
PU
04/04OXURION : NV announces full enrollment of its Phase 2 trial evaluating efficacy ..
GL
03/07OXURION : Business Update - FY 2018
AQ
03/04OXURION NV : annual earnings release
02/28OXURION : NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition f..
GL
2018OXURION : licences heparanase blockers from Beta Therapeutics
AQ
2018OXURION : and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatme..
PU
2018OXURION : November is Diabetic Eye Disease Awareness Month at Prevent Blindness
PU
2018OXURION : Announces the Appointment of Adrienne Graves to its Board of Directors
PU
More news
Analyst Recommendations on OXURION
More recommendations
Sector news : Biotechnology & Medical Research - NEC
04/16GILEAD SCIENCES : Insitro to Collaborate on Nonalcoholic Steatohepatitis
DJ
04/15PATRICK THOMAS : Novartis Files Application for Macular Degeneration Treatment
DJ
04/12GILEAD SCIENCES : Novo Nordisk Plan NASH Collaboration
DJ
04/08GSK wins U.S. nod for two-drug HIV combination
RE
04/08Sanofi, Alnylam Complete Research Phase of Rare Disease Alliance
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart OXURION
Duration : Period :
Oxurion Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OXURION
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 5,75 €
Spread / Average Target 49%
Managers
NameTitle
Patrik de Haes Chief Executive Officer & Executive Director
Thomas Moragne Clay Chairman
Dominique Vanfleteren Chief Financial Officer
Susan Schneider Chief Medical Officer
David R. Guyer Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
OXURION6.49%166
IQVIA HOLDINGS INC15.67%26 285
CELLTRION, INC.--.--%24 574
LONZA GROUP16.76%21 828
INCYTE CORPORATION15.84%15 847
EXACT SCIENCES CORPORATION43.69%11 596